Related references
Note: Only part of the references are listed.CDK4/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal
Lisa Crozier et al.
EMBO JOURNAL (2022)
CDK4 and CDK6 kinases: From basic science to cancer therapy
Anne Fassl et al.
SCIENCE (2022)
Hallmarks of Cancer: New Dimensions
Douglas Hanahan
CANCER DISCOVERY (2022)
Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer
Yang Yang et al.
CELL DEATH AND DIFFERENTIATION (2022)
In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
Thibault Passeri et al.
FRONTIERS IN ONCOLOGY (2022)
LncRNA SNHG17 interacts with LRPPRC to stabilize c-Myc protein and promote G1/S transition and cell proliferation
Jin-Yu Liu et al.
CELL DEATH & DISEASE (2021)
LRPPRC regulates redox homeostasis via the circANKHD1/FOXM1 axis to enhance bladder urothelial carcinoma tumorigenesis
Wen-Su Wei et al.
REDOX BIOLOGY (2021)
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
Xuewei Wu et al.
NATURE CANCER (2021)
In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101
Laura Masuelli et al.
INVESTIGATIONAL NEW DRUGS (2020)
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors
Mark N. Stein et al.
INVESTIGATIONAL NEW DRUGS (2020)
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Monica Alvarez-Fernandez et al.
CANCER CELL (2020)
Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma
Jessica L. F. Teh et al.
MOLECULAR CANCER THERAPEUTICS (2020)
A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic/apyrimidinic endonuclease 1
Yuxiao Wang et al.
INVESTIGATIONAL NEW DRUGS (2020)
Macrophage secretion of miR-106b-5p causes renin-dependent hypertension
J. Oh et al.
NATURE COMMUNICATIONS (2020)
Poly (A) tail length of human mitochondrial mRNAs is tissue-specific and a mutation in LRPPRC results in transcript-specific patterns of deadenylation
Shamisa Honarmand et al.
MOLECULAR GENETICS AND METABOLISM REPORTS (2020)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
Luigi Formisano et al.
NATURE COMMUNICATIONS (2019)
MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
Liam Cornell et al.
CELL REPORTS (2019)
Energetic Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy
Marco Fiorillo et al.
FRONTIERS IN ONCOLOGY (2019)
Horizontal Cell Biology: Monitoring Global Changes of Protein Interaction States with the Proteome-Wide Cellular Thermal Shift Assay (CETSA)
Lingyun Dai et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 88 (2019)
Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells
Olivia Morris-Hanon et al.
MOLECULAR NEUROBIOLOGY (2019)
LRPPRC: A Multifunctional Protein Involved in Energy Metabolism and Human Disease
Jie Cui et al.
FRONTIERS IN PHYSIOLOGY (2019)
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma
Hao Xie et al.
INVESTIGATIONAL NEW DRUGS (2019)
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
Anna E. Vilgelm et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Proteasome-Independent Protein Knockdown by Small-Molecule Inhibitor for the Undruggable Lung Adenocarcinoma
Wei Zhou et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2019)
Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
Jessica L. F. Teh et al.
CLINICAL CANCER RESEARCH (2019)
DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression
Ziyue Chen et al.
MOLECULAR THERAPY (2019)
Mitochondrial Damage Mediated by miR-1 Overexpression in Cancer Stem Cells
Song Zhang et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
TGIF2 promotes the progression of lung adenocarcinoma by bridging EGFR/RAS/ERK signaling to cancer cell stemness
Renle Du et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Zhiqiang Li et al.
CANCER CELL (2018)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
RNA Chemical Proteomics Reveals the N6-Methyladenosine (m6A)-Regulated Protein-RNA Interactome
A. Emilia Arguello et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Haizhen Wang et al.
NATURE (2017)
LRPPRC-mediated folding of the mitochondrial transcriptome
Stefan J. Siira et al.
NATURE COMMUNICATIONS (2017)
Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System
Stephen T. Hallett et al.
CELL REPORTS (2017)
Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis
Eldad Zacksenhaus et al.
TRENDS IN CANCER (2017)
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation
A-S Tigan et al.
ONCOGENE (2016)
Targeting CDK4 and CDK6: From Discovery to Therapy
Charles J. Sherr et al.
CANCER DISCOVERY (2016)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Targeting the RB-E2F pathway in breast cancer
J. Johnson et al.
ONCOGENE (2016)
Nutrient sensing by the mitochondrial transcription machinery dictates oxidative phosphorylation
Lijun Liu et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
The Kinase-Independent, Second Life of CDK6 in Transcription
Tobias Otto et al.
CANCER CELL (2013)
LRPPRC is necessary for polyadenylation and coordination of translation of mitochondrial mRNAs
Benedetta Ruzzenente et al.
EMBO JOURNAL (2012)
Role of leucine-rich pentatricopeptide repeat motif-containing protein (LRPPRC) for anti-apoptosis and tumourigenesis in cancers
Tian Tian et al.
EUROPEAN JOURNAL OF CANCER (2012)
A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer
Maria Q. Baggstrom et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
The Bcl-2 Homology Domain 3 Mimetic Gossypol Induces Both Beclin 1-dependent and Beclin 1-independent Cytoprotective Autophagy in Cancer Cells
Ping Gao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment
Giulia Bertolini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Share Paper
